Abstract The UK National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of erlotinib (Roche) to submit evidence for the clinical and cost effectiveness of …

Erlotinib (Tarceva®), an oral epidermal growth factor receptor tyrosine kinase inhibitor, is
associated with modest improvements in survival in patients with advanced non-small cell …

Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …

Objectives: A recent phase III trial showed that patients with advanced non-small cell lung
cancer (NSCLC) whose tumors harbor specific EGFR mutations significantly benefit from first …

Background Platinum-doublet, first-line treatment of locally advanced or metastatic non-
small cell lung cancer (NSCLC) is limited to 4–6 cycles. An alternative strategy used to …

Abstract Background The NCIC Clinical Trials Group conducted the BR. 21 trial, a
randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine …

Objective: Assess the budgetary impact of adding erlotinib for maintenance therapy (MTx) in
advanced non-small cell lung cancer (NSCLC) from a US health plan perspective. Methods …

The estimated costs of second-line therapy with erlotinib versus docetaxel or pemetrexed
were analysed in patients with advanced non-small cell lung cancer (NSCLC) assuming the …

Background Lung cancer is the second most diagnosed cancer in the UK. Over 70% of lung
cancers are non-small cell lung cancers (NSCLCs). Patients with stage III or IV NSCLC may …

BACKGROUND: Various drug therapies are available for treatment of refractory stage IIIB/IV
non-small cell lung cancer (NSCLC), but their comparative economic value is unclear …